127 related articles for article (PubMed ID: 27178938)
21. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells.
Verma UN; Surabhi RM; Schmaltieg A; Becerra C; Gaynor RB
Clin Cancer Res; 2003 Apr; 9(4):1291-300. PubMed ID: 12684397
[TBL] [Abstract][Full Text] [Related]
22. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.
Yhee JY; Song S; Lee SJ; Park SG; Kim KS; Kim MG; Son S; Koo H; Kwon IC; Jeong JH; Jeong SY; Kim SH; Kim K
J Control Release; 2015 Jan; 198():1-9. PubMed ID: 25481438
[TBL] [Abstract][Full Text] [Related]
23. Fine-tuned PEGylation of chitosan to maintain optimal siRNA-nanoplex bioactivity.
Guţoaia A; Schuster L; Margutti S; Laufer S; Schlosshauer B; Krastev R; Stoll D; Hartmann H
Carbohydr Polym; 2016 Jun; 143():25-34. PubMed ID: 27083340
[TBL] [Abstract][Full Text] [Related]
24. Co-delivery of hypoxia inducible factor-1α small interfering RNA and 5-fluorouracil to overcome drug resistance in gastric cancer SGC-7901 cells.
Chen Y; Sun L; Guo D; Wu Z; Chen W
J Gene Med; 2017 Dec; 19(12):. PubMed ID: 29106062
[TBL] [Abstract][Full Text] [Related]
25. Chitosan (CMD)-mediated co-delivery of SN38 and Snail-specific siRNA as a useful anticancer approach against prostate cancer.
Afkham A; Aghebati-Maleki L; Siahmansouri H; Sadreddini S; Ahmadi M; Dolati S; Afkham NM; Akbarzadeh P; Jadidi-Niaragh F; Younesi V; Yousefi M
Pharmacol Rep; 2018 Jun; 70(3):418-425. PubMed ID: 29626645
[TBL] [Abstract][Full Text] [Related]
26. A novel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and in vitro analysis.
Malhotra M; Lane C; Tomaro-Duchesneau C; Saha S; Prakash S
Int J Nanomedicine; 2011; 6():485-94. PubMed ID: 21562608
[TBL] [Abstract][Full Text] [Related]
27. GABA
Ni S; Liu Y; Tang Y; Chen J; Li S; Pu J; Han L
Carbohydr Polym; 2018 Jan; 179():135-144. PubMed ID: 29111036
[TBL] [Abstract][Full Text] [Related]
28. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
29. Preparation and characterization of chitosan/polyguluronate nanoparticles for siRNA delivery.
Lee DW; Yun KS; Ban HS; Choe W; Lee SK; Lee KY
J Control Release; 2009 Oct; 139(2):146-52. PubMed ID: 19567259
[TBL] [Abstract][Full Text] [Related]
30. Rolling circle transcription-based polymeric siRNA nanoparticles for tumor-targeted delivery.
Lee JH; Ku SH; Kim MJ; Lee SJ; Kim HC; Kim K; Kim SH; Kwon IC
J Control Release; 2017 Oct; 263():29-38. PubMed ID: 28373128
[TBL] [Abstract][Full Text] [Related]
31. Nebulised siRNA encapsulated crosslinked chitosan nanoparticles for pulmonary delivery.
Sharma K; Somavarapu S; Colombani A; Govind N; Taylor KM
Int J Pharm; 2013 Oct; 455(1-2):241-7. PubMed ID: 23876499
[TBL] [Abstract][Full Text] [Related]
32. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM
Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment.
Wang J; Feng SS; Wang S; Chen ZY
Int J Pharm; 2010 Nov; 400(1-2):194-200. PubMed ID: 20801205
[TBL] [Abstract][Full Text] [Related]
34. Chitosan-based nanoparticles for mucosal delivery of RNAi therapeutics.
Martirosyan A; Olesen MJ; Howard KA
Adv Genet; 2014; 88():325-52. PubMed ID: 25409611
[TBL] [Abstract][Full Text] [Related]
35. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo.
Lee SJ; Yook S; Yhee JY; Yoon HY; Kim MG; Ku SH; Kim SH; Park JH; Jeong JH; Kwon IC; Lee S; Lee H; Kim K
J Control Release; 2015 Dec; 220(Pt B):631-41. PubMed ID: 26307351
[TBL] [Abstract][Full Text] [Related]
36. Transferrin functionalized chitosan-PEG nanoparticles for targeted delivery of paclitaxel to cancer cells.
Nag M; Gajbhiye V; Kesharwani P; Jain NK
Colloids Surf B Biointerfaces; 2016 Dec; 148():363-370. PubMed ID: 27632697
[TBL] [Abstract][Full Text] [Related]
37. Chitosan Nanoparticles for SiRNA Delivery In Vitro.
Ragelle H; Vanvarenberg K; Vandermeulen G; Préat V
Methods Mol Biol; 2016; 1364():143-50. PubMed ID: 26472448
[TBL] [Abstract][Full Text] [Related]
38. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
[TBL] [Abstract][Full Text] [Related]
39. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
Yang XZ; Dou S; Sun TM; Mao CQ; Wang HX; Wang J
J Control Release; 2011 Dec; 156(2):203-11. PubMed ID: 21839126
[TBL] [Abstract][Full Text] [Related]
40. Polymer nanoassemblies with hydrophobic pendant groups in the core induce false positive siRNA transfection in luciferase reporter assays.
Rheiner S; Reichel D; Rychahou P; Izumi T; Yang HS; Bae Y
Int J Pharm; 2017 Aug; 528(1-2):536-546. PubMed ID: 28629980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
